Ryusendo to Officially Launch European Joint Care Ingredient 'Collavant® n2' in Japan

龍泉堂公司取得西班牙Bioiberica獨家代理權,將於日本正式發售歐洲產的關節保健原料「Collavant® n2」非變性II型膠原蛋白。
保健原料,產品上市,獨家代理NQ 80/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 18, 2026 at 19:00
  • 🔍 Collected: May 18, 2026 at 10:31
  • 🤖 AI Analyzed: May 18, 2026 at 10:48 (16 min after Collected)
Ryusendo Co., Ltd. (HQ: Toshima-ku, Tokyo; CEO: Yoshiaki Shiojima) will officially launch 'Collavant® n2,' a functional ingredient for joint care manufactured by Spain's Bioiberica, in Japan on May 27, 2026. Ryusendo has acquired exclusive distribution rights for the globally branded ingredient in Japan. The company will now begin full-scale promotion of the ingredient for joint health maintenance, active seniors, sports nutrition, and anti-aging sectors. The ingredient will also be featured at a seminar and exhibition booth at 'ifia JAPAN 2026.' ◆ A Next-Generation Joint Care Ingredient Focused on Oral Tolerance: Collavant® n2 is a high-quality, undenatured type II collagen derived from chicken sternum cartilage. Manufactured with a unique European process that preserves the collagen's specific 3D structure, it functions through a mechanism called 'oral tolerance.' A small dose works by modulating the body's excessive immune response to its own type II collagen, thereby supporting joint health. ◆ Clinical Trials Confirm Improved Joint Function and Cartilage Protection: Multiple double-blind clinical studies on healthy subjects experiencing joint discomfort during exercise have shown significant improvements in KOOS scores (a measure of knee injury and osteoarthritis) and a confirmed 18.3% decrease in urinary CTX-II (a biomarker for cartilage degradation) in the Collavant® n2 group, compared to a 20.6% increase in the placebo group. These results demonstrate that Collavant® n2 is a scientifically-backed ingredient for joint care. ◆ Small 40mg Daily Dose Allows for Wide Product Formulation: The recommended daily intake is only 40mg, containing at least 2.4mg of undenatured type II collagen. This low dosage allows for easy application in various product forms, such as hard capsules, tablets, beverages, and gummies. Its neutral flavor and cost-effectiveness also make it suitable for combination with existing formulas (e.g., glucosamine). ◆ A High-Quality Branded Ingredient from European Leader Bioiberica: Manufacturer Bioiberica is a leading Spanish company in the life sciences sector. Collavant® n2 is part of its mobility brand portfolio and has been adopted by major global companies like Abbott and Bayer. By adding Collavant® n2 to its existing portfolio, which includes 'NEXT-Ⅱ®,' Ryusendo aims to strengthen its lineup in the Japanese undenatured type II collagen and joint care markets.